Abstract
No public abstract is available from the verified source records.
Katharine A Smith, Spyridon Siafis, Robert A McCutcheon, Toby Pillinger, Rachel Upthegrove, James Downs, Emma L Lawrance, Ilina Singh, Jennifer Potts, Claudia Sartor, Charles Mudenge, Andrea Cipriani
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Trends and cross-country inequalities in schizophrenia from 1990 to 2021, with prediction to 2035: a systematic analysis of the global burden of disease study 2021
10.1186/s12888-025-07273-6 · 2025
Unresolved referenced work
2025
Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages
10.1002/wps.70066 · 2026
INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia
10.1016/s2215-0366(25)00031-8 · 2025
The relationship between the duration of untreated psychosis and outcome in low-and-middle income countries: a systematic review and meta analysis
10.1016/j.schres.2009.01.008 · 2009
Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors
10.1002/wps.20994 · 2022
Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum disorder
10.1001/jamanetworkopen.2024.38358 · 2024
Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases
10.1016/s0140-6736(25)02365-7 · 2026
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Schizophrenia
10.1038/s41572-025-00667-6 · 2025
Access to medicines through health systems in low- and middle-income countries
10.1093/heapol/czz119 · 2019
New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis
10.1136/bmjment-2023-300759 · 2023
Digital mental health: challenges and next steps
10.1136/bmjment-2023-300670 · 2023
Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement
10.1136/bmj-2022-070849 · 2022
Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology
10.1176/appi.ajp.2016.16050503 · 2017
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
10.1007/s00406-018-0869-3 · 2018
Digital mental health for schizophrenia and other severe mental illnesses: an international consensus on current challenges and potential solutions
10.2196/57155 · 2024
Engagement and attrition in digital mental health: current challenges and potential solutions
10.1038/s41746-025-01778-w · 2025
Digital health interventions for schizophrenia: setting standards for mental health
10.1016/j.schres.2024.04.013 · 2024
Beyond counting clicks: rethinking engagement in digital mental health
10.1192/bjp.2025.10485 · 2025
ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi
10.1371/journal.pmed.1004326 · 2024
Global mental health research and practice: a decolonial approach
10.1016/s2215-0366(22)00043-8 · 2022
The Lancet and colonialism: past, present, and future
10.1016/s0140-6736(24)00102-8 · 2024
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
10.1016/s2215-0366(22)00304-2 · 2022
Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis
10.1016/j.eclinm.2026.103847 · 2026
Data-driven taxonomy for antipsychotic medication: a new classification system
10.1016/j.biopsych.2023.04.004 · 2023
A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature
10.1016/j.euroneuro.2015.08.019 · 2015
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
10.1371/journal.pmed.1003082 · 2020
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
10.1016/s0140-6736(19)31135-3 · 2019
Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development
10.1016/s2215-0366(23)00262-6 · 2023
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
10.1016/s2215-0366(19)30416-x · 2020
Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis
10.1093/ijnp/pyae052 · 2024
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
10.1097/yic.0000000000000371 · 2021
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: a systematic review and meta-analysis
10.1016/j.euroneuro.2024.11.013 · 2025
Efficacy, acceptability and side-effects of oral versus long-acting-injectables antipsychotics: systematic review and network meta-analysis
10.1016/j.euroneuro.2024.03.003 · 2024
Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis
10.1002/wps.21089 · 2023
Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis
10.1016/j.euroneuro.2018.03.008 · 2018
Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses
10.1016/s2215-0366(17)30270-5 · 2017
Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis
10.1016/j.euroneuro.2018.09.007 · 2018
Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis
10.1016/j.euroneuro.2018.11.1105 · 2019
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
10.1016/s0140-6736(21)01997-8 · 2022
Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission
10.1016/s2215-0366(25)00162-2 · doi-reference
Democratizing clinical research
10.1038/474277a · doi-reference
Beyond the methodological binary: coproduction as the third pillar of mental health science
10.1136/bmjment-2025-301807 · doi-reference
Community study of knowledge of and attitude to mental illness in Nigeria
10.1192/bjp.186.5.436 · doi-reference
Effect of collaborative care between traditional and faith healers and primary health-care workers on psychosis outcomes in Nigeria and Ghana (COSIMPO): a cluster randomised controlled trial
10.1016/s0140-6736(20)30634-6 · doi-reference
Early intervention in psychosis and management of first episode psychosis in low-and lower-middle-income countries: a systematic review
10.1093/schbul/sbae025 · doi-reference
Antipsychotic medication in sub-Saharan Africa: a systematic literature review
10.1097/jcp.0000000000001282 · doi-reference
Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?
10.1186/1752-4458-6-9 · doi-reference
Education versus screening: the use of capacity to consent tools in psychiatric genomics
10.1136/medethics-2019-105396 · doi-reference
A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia
10.1007/s40263-022-00932-2 · doi-reference
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis
10.1192/bjp.2025.89 · doi-reference
Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice
10.1016/j.euroneuro.2024.04.012 · doi-reference
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis
10.1016/s2215-0366(24)00314-6 · doi-reference
The epidemiology of psychiatric disorders in Africa: a scoping review
10.1016/s2215-0366(21)00009-2 · doi-reference
Medications, epilepsy and climate change: added layers of complexity
10.1002/bcp.70108 · doi-reference
Susceptibility of persons with schizophrenia to extreme heat: a critical review of physiological, behavioural, and social factors
10.1016/j.scitotenv.2025.179965 · doi-reference
The apportionment of pharmacogenomic variation: race, ethnicity, and adverse drug reactions
10.18103/mra.v10i9.2986 · doi-reference
Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference?
10.1186/1756-0500-1-25 · doi-reference
Loneliness in psychosis: a meta-analytical review
10.1093/schbul/sbx036 · doi-reference
The use of long-acting injectables for people with schizophrenia: consensus panel recommendations for overcoming barriers and implementing treatment
10.1007/s40120-025-00838-3 · doi-reference
Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants
10.1002/wps.20972 · doi-reference
An online evidence-based dictionary of common adverse events of antidepressants: a new tool to empower patients and clinicians in their shared decision-making process
10.1186/s12888-024-05950-6 · doi-reference
A decision-support system to personalize antidepressant treatment in major depressive disorder: a randomized clinical trial
10.1001/jama.2026.1327 · doi-reference
“Short” versus “long” duration of untreated psychosis in people with first-episode psychosis: a systematic review and meta-analysis of baseline status and follow-up outcomes
10.1093/schbul/sbae201 · doi-reference
The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis
10.1002/wps.20822 · doi-reference
Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
10.1192/j.eurpsy.2022.11 · doi-reference
Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials
10.1001/jamapsychiatry.2021.3990 · doi-reference
Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors
10.1176/appi.ajp.2017.16121358 · doi-reference
Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis
10.1038/s41386-019-0440-6 · doi-reference
Antipsychotic augmentation vs monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
10.1002/wps.20387 · doi-reference
Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis
10.1192/bjp.2023.27 · doi-reference
Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics
10.1016/j.schres.2016.07.018 · doi-reference
Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis
10.1016/s2352-4642(24)00098-1 · doi-reference
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
10.1016/s0140-6736(17)30060-0 · doi-reference
Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies
10.1001/jamapsychiatry.2019.1702 · doi-reference
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies
10.1016/s2215-0366(21)00039-0 · doi-reference
Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study
10.1093/schbul/sbab063 · doi-reference
Antipsychotic drug dosing and study discontinuation in schizophrenia: a systematic review and dose-response meta-analysis
10.1016/j.euroneuro.2025.02.012 · doi-reference
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
10.1038/s41380-023-02203-y · doi-reference
Antipsychotic-related prolactin changes: a systematic review and dose-response meta-analysis
10.1007/s40263-025-01218-z · doi-reference